Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monopar Therapeutics Inc. - Common Stock (NQ:MNPR)

82.64 +1.07 (+1.31%)
Streaming Delayed Price Updated: 1:58 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 104,497
Open 80.38
Bid (Size) 81.53 (1)
Ask (Size) 84.28 (1)
Prev. Close 81.57
Today's Range 80.38 - 87.00
52wk Range 12.55 - 105.00
Shares Outstanding 14,157,941
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga

Performance

YTD
+271.9%
+271.9%
1 Month
+7.8%
+7.8%
3 Month
+90.4%
+90.4%
6 Month
+102.5%
+102.5%
1 Year
+363.5%
+363.5%

More News

Read More
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
From Monopar Therapeutics Inc.
Via GlobeNewswire
Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout
Via Investor's Business Daily
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
3 Momentum Stocks Soaring Into 2025 and Beyond
Via MarketBeat
Topics Stocks
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
From Monopar Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga

Frequently Asked Questions

Is Monopar Therapeutics Inc. - Common Stock publicly traded?
Yes, Monopar Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Monopar Therapeutics Inc. - Common Stock trade on?
Monopar Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Monopar Therapeutics Inc. - Common Stock?
The ticker symbol for Monopar Therapeutics Inc. - Common Stock is MNPR on the Nasdaq Stock Market
What is the current price of Monopar Therapeutics Inc. - Common Stock?
The current price of Monopar Therapeutics Inc. - Common Stock is 82.64
When was Monopar Therapeutics Inc. - Common Stock last traded?
The last trade of Monopar Therapeutics Inc. - Common Stock was at 10/27/25 01:58 PM ET
What is the market capitalization of Monopar Therapeutics Inc. - Common Stock?
The market capitalization of Monopar Therapeutics Inc. - Common Stock is 1.17B
How many shares of Monopar Therapeutics Inc. - Common Stock are outstanding?
Monopar Therapeutics Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.